Article Text

Download PDFPDF
Spinocerebellar ataxia type 17 associated with an expansion of 42 glutamine residues in TATA-box binding protein gene
  1. D Nolte1,
  2. E Sobanski2,
  3. A Wißen1,3,
  4. J U Regula4,
  5. C Lichy4,
  6. U Müller1
  1. 1Institut für Humangenetik, Justus-Liebig Universität Giessen, Germany
  2. 2Zentralinstitut für Seelische Gesundheit, Mannheim, Germany
  3. 3Klinik für Augenheilkunde, Universitätsklinikum Schleswig-Holstein Campus Kiel, Germany
  4. 4Neurologische Klinik, Universitätsklinikum Heidelberg, Germany
  1. Correspondence to Dr Dagmar Nolte, Institut für Humangenetik, Justus-Liebig Universität Giessen, Schlangenzahl 14, 35392 Giessen, Germany; dagmar.nolte{at}humangenetik.med.uni-giessen.de

Abstract

Background Spinocerebellar ataxia type 17 (SCA17) is caused by abnormal expansions of CAG/CAA trinucleotides within the TATA-box binding protein gene (TBP). The currently accepted critical threshold of abnormal expansions is ≥43.

Objective To investigate the minimal CAG/CAA expansion within the TBP in SCA17.

Results 285 patients with autosomal-dominant ataxia were examined, and abnormal or borderline expansions of CAG/CAA within TBP in eight cases were found. Of those, four patients from three families had exactly 42 CAG/CAA trinucleotides, that is, one codon less than the currently accepted critical threshold of 43. The four patients presented with a relatively benign phenotype. All had dysdiadochokinesia and dysarthria. Mild gait ataxia was observed in three of the four patients.

Conclusion The reference definition of at least 43 CAG/CAA codons for pathological SCA17 alleles should be lowered to 42.

  • Spinocerebellar ataxia type 17
  • SCA17
  • TBP
  • repeat expansion

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.